ELAPOR1

Across TCGA pan-cancer cohorts, ELAPOR1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ELAPOR1’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ELAPOR1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ELAPOR1 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

PDAC, LUAD, and HNSC are the cancer types where ELAPOR1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ELAPOR1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	−2.198	<.001	8	view →
LUAD	Female	All	+0.943	<.001	7	view →
HNSC	Male	II,III,IV	−0.679	.005	4	view →
LSCC	Male	All	+0.435	<.001	4	view →
CCRCC	All	All	+0.302	.004	4	view →
OV	All	All	+1.429	.048	2	view →
COAD	Female	IV	−1.260	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ELAPOR1–PDAC

Open the PDAC breakdown →